cutaneous metastases
Recently Published Documents


TOTAL DOCUMENTS

624
(FIVE YEARS 112)

H-INDEX

31
(FIVE YEARS 3)

2022 ◽  
Vol 10 (1) ◽  
pp. 345-352
Author(s):  
Zhong-Hui Li ◽  
Fang Wang ◽  
Ping Zhang ◽  
Peng Xue ◽  
Shi-Jie Zhu

2022 ◽  
pp. 285-286
Author(s):  
Werner Kempf ◽  
Markus Hantschke ◽  
Heinz Kutzner
Keyword(s):  

2021 ◽  
Author(s):  
Mario E. Lacouture ◽  
Shari B. Goldfarb ◽  
Alina Markova ◽  
Sant P. Chawla ◽  
Karan V. Dewnani ◽  
...  

Abstract Purpose: This Phase 1/2 study evaluated safety and efficacy of a topical submicron particle paclitaxel (SPP) in an anhydrous ointment base (SOR007), primarily in breast cancer patients with cutaneous metastases (CM).Methods: One of 3 concentrations of SOR007 SPP (0.15%, 1.0%, or 2.0%) was applied twice daily over an area of 50 cm2 under a 3+3 phase I design for up to 28 days, with the option for additional 28 days at the highest dose once safety was established. Efficacy was analyzed by lesion measurements and photographs to determine overall response rate (ORR), complete response (CR) and progression free survival by day 28 or 56.Results: Twenty-three subjects were enrolled, 21 with cutaneous metastases of breast cancer (CMOBC). Four subjects received SOR007 0.15%, three at a dose of 1.0% for a median of 28 days (range = 6 to 29 days), and sixteen at 2.0% for a median of 56 days (range = 42 to 60). All doses were well tolerated, and 19 subjects were evaluable for efficacy. At day 28 across all dose levels, 16% (95%CI: 3.4 to 39.6%) of subjects achieved an ORR and another 63.1% (95%CI: 34.9 to 96.8%) had stable disease (SD). The proportion of patients being progression free at 28 days across all treatments was 79% (95:CI: 54 to 94%). Conclusion: Application of SOR007 0.15%, 1.0%, and 2.0% to CM resulted in lesion stabilization or response in most subjects, with reduced lesion pain, and minimal systemic absorption of paclitaxel. A randomized, placebo-controlled trial to confirm these findings is warranted.NCT: #03101358


2021 ◽  
Vol 11 ◽  
Author(s):  
Nan Wang ◽  
Lin Li ◽  
Youyi Xiong ◽  
Jiangrui Chi ◽  
Xinwei Liu ◽  
...  

BackgroundBreast cancer (BC) is the most common tumor to develop cutaneous metastases. Most BCs with cutaneous metastasis are human epidermal growth factor receptor 2 (HER2)-positive subtypes. Although the molecular mechanisms of breast cancer metastasis to different sites and the corresponding treatment methods are areas of in-depth research, there are few studies on cutaneous metastasis.Case PresentationFive HER2-positive BC patients with extensive cutaneous metastases were treated with a regimen containing pyrotinib, a novel small-molecule tyrosine kinase inhibitor that irreversibly blocks epidermal growth factor receptor (EGFR), HER2, and human epidermal growth factor receptor 4 (HER4), then their cutaneous metastases quickly resolved at an astonishing speed and their condition was well controlled during the follow-up period.ConclusionsThis case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. Based on this, we recommend that pyrotinib can be used as a supplement to trastuzumab for HER2-positive BC patients with cutaneous metastases. In addition, we should consider that the pan-inhibitory effect of pyrotinib on EGFR, HER2, and HER4 may provide a dual therapeutic effect against HER2 and mucin 1.


Cureus ◽  
2021 ◽  
Author(s):  
Isabel Betlloch-Mas ◽  
Tamara Soriano-García ◽  
Ignacio Boira ◽  
Juan Carlos Palazón ◽  
Gloria Juan-Carpena ◽  
...  

2021 ◽  
Vol 8 (12) ◽  
pp. 3699
Author(s):  
Tahmina Jahan Lata ◽  
Dilip Gahankari ◽  
Colin Arnold

Cutaneous metastases of oesophageal adenocarcinoma are uncommon. Several different sites of metastases including skin and lip has been reported.  However, metastases to the scalp is an extremely rare event. We present a unique case of oesophageal adenocarcinoma metastasis to the scalp. Further, a discussion is offered on the mechanism of route of spread from the oesophagus to the scalp.  


Author(s):  
Rachel E. Reingold ◽  
Brooke E. Corbett ◽  
Nina R. Blank ◽  
Rachel A. Day ◽  
Michael J. McManus ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Haiqing Wang ◽  
Chengbei Bao ◽  
Ting Gong ◽  
Chao Ji

Breast carcinoma en cuirasse (CeC) is an extremely rare form of cutaneous metastases of breast cancer, characterized by diffuse sclerodermoid induration of the skin. It may be difficult to distinguish CeC from some skin diseases, including postirradiation morphea, inflammatory breast cancer, radiation dermatitis, and other cutaneous metastases, but it can be easily discerned by histology. Because of the small number of documented cases, the treatment consensus has not been clearly defined. Here, we show a 45-year-old woman with grade III infiltrating ductal carcinoma manifesting as CeC to the chest wall. Early diagnosis and treatment are essential to prevent the catastrophic natural progression of this rare malignancy.


2021 ◽  
Vol 15 ◽  
Author(s):  
Nkechi Enechukwu ◽  
Ezejiofor Ogochukwu Ifeanyi ◽  
Gabriel Olabiyi Ogun ◽  
Adebola Olufunmilayo Ogunbiyi

Sign in / Sign up

Export Citation Format

Share Document